Nuance Investments LLC Makes New Investment in Henry Schein, Inc. (NASDAQ:HSIC)

Nuance Investments LLC acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,366,347 shares of the company's stock, valued at approximately $103,446,000. Henry Schein makes up about 2.4% of Nuance Investments LLC's investment portfolio, making the stock its 12th largest position. Nuance Investments LLC owned 1.05% of Henry Schein at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Henry Schein by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company's stock valued at $353,898,000 after buying an additional 53,506 shares during the last quarter. American Century Companies Inc. raised its stake in Henry Schein by 7.3% during the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company's stock worth $350,392,000 after purchasing an additional 322,649 shares during the period. Boston Partners grew its stake in shares of Henry Schein by 144.1% during the 4th quarter. Boston Partners now owns 2,637,429 shares of the company's stock valued at $199,393,000 after buying an additional 1,556,831 shares during the period. Northern Trust Corp increased its holdings in shares of Henry Schein by 2.8% during the 3rd quarter. Northern Trust Corp now owns 1,647,889 shares of the company's stock worth $122,356,000 after buying an additional 45,561 shares during the last quarter. Finally, Lazard Asset Management LLC increased its holdings in shares of Henry Schein by 1,303.3% during the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company's stock worth $92,614,000 after buying an additional 1,158,451 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

HSIC traded down $0.13 during trading hours on Friday, reaching $73.31. The company's stock had a trading volume of 850,463 shares, compared to its average volume of 1,078,406. The company's 50-day moving average is $72.88 and its 200-day moving average is $72.46. Henry Schein, Inc. has a 52 week low of $60.01 and a 52 week high of $82.63. The firm has a market cap of $9.42 billion, a PE ratio of 24.77, a price-to-earnings-growth ratio of 1.92 and a beta of 0.87. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.00 and a current ratio of 1.75.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The firm's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 5.08 EPS for the current year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the firm's stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company's stock, valued at approximately $5,430,462.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Bradford C. Connett sold 6,430 shares of the company's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. UBS Group reduced their target price on shares of Henry Schein from $82.00 to $80.00 and set a "neutral" rating on the stock in a report on Wednesday. Leerink Partnrs restated a "market perform" rating on shares of Henry Schein in a research report on Monday, February 26th. Jefferies Financial Group raised their price target on shares of Henry Schein from $74.00 to $81.00 and gave the company a "hold" rating in a research note on Wednesday, March 6th. Piper Sandler lifted their target price on Henry Schein from $78.00 to $86.00 and gave the company an "overweight" rating in a research note on Monday, February 26th. Finally, TheStreet raised shares of Henry Schein from a "c+" rating to a "b-" rating in a research note on Monday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $81.73.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.